These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32237002)

  • 41. Factors Predicting Fecal Occult Blood Testing among Residents of Bushehr, Iran, Based on the Health Belief Model.
    Ghobadi Dashdebi K; Noroozi A; Tahmasebi R
    Asian Pac J Cancer Prev; 2016; 17(S3):17-22. PubMed ID: 27165201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy?
    van Dam L; Korfage IJ; Kuipers EJ; Hol L; van Roon AH; Reijerink JC; van Ballegooijen M; van Leerdam ME
    Eur J Cancer; 2013 Jul; 49(10):2321-30. PubMed ID: 23571149
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A combination of clinical risk stratification and fecal immunochemical test is useful for identifying persons with high priority of early colonoscopy.
    Jung YS; Park CH; Kim NH; Park JH; Park DI; Sohn CI
    Dig Liver Dis; 2018 Mar; 50(3):254-259. PubMed ID: 29198569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inequalities in cancer screening participation: examining differences in perceived benefits and barriers.
    Smith SG; McGregor LM; Raine R; Wardle J; von Wagner C; Robb KA
    Psychooncology; 2016 Oct; 25(10):1168-1174. PubMed ID: 27309861
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Barriers and facilitators to colonoscopy following fecal immunochemical test screening for colorectal cancer: A key informant interview study.
    Kerrison RS; Travis E; Dobson C; Whitaker KL; Rees CJ; Duffy SW; von Wagner C
    Patient Educ Couns; 2022 Jun; 105(6):1652-1662. PubMed ID: 34607734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Psychiatric morbidity and screening for colorectal cancer.
    Parker MA; Robinson MH; Scholefield JH; Hardcastle JD
    J Med Screen; 2002; 9(1):7-10. PubMed ID: 11943790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety-net health system.
    Singal AG; Gupta S; Tiro JA; Skinner CS; McCallister K; Sanders JM; Bishop WP; Agrawal D; Mayorga CA; Ahn C; Loewen AC; Santini NO; Halm EA
    Cancer; 2016 Feb; 122(3):456-63. PubMed ID: 26535565
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A systematic review of the psychological impact of false-positive colorectal cancer screening: What is the role of the general practitioner?
    van der Velde JL; Blanker MH; Stegmann ME; de Bock GH; Berger MY; Berendsen AJ
    Eur J Cancer Care (Engl); 2017 May; 26(3):. PubMed ID: 28493375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of presenting information about invasive follow-up testing on individuals' noninvasive colorectal cancer screening participation decision: results from a discrete choice experiment.
    Benning TM; Dellaert BG; Severens JL; Dirksen CD
    Value Health; 2014 Jul; 17(5):578-87. PubMed ID: 25128051
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Questionnaire Survey on the Sequence of Events Prior to Undergoing Colonoscopy: The Influence of the Behavioral Response after a Fecal Occult Blood Test on the Early Detection of Colorectal Cancer.
    Yuge R; Fujii T; Shinagawa K; Sanomura Y; Oka S; Nagashima S; Ohisa M; Kitadai Y; Tanaka S; Kohno N; Tanaka J
    Intern Med; 2019 Jun; 58(11):1541-1547. PubMed ID: 30713310
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A combination of clinical risk stratification and fecal immunochemical test results to prioritize colonoscopy screening in asymptomatic participants.
    Aniwan S; Rerknimitr R; Kongkam P; Wisedopas N; Ponuthai Y; Chaithongrat S; Kullavanijaya P
    Gastrointest Endosc; 2015 Mar; 81(3):719-27. PubMed ID: 25708760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in health behavior 1 year after testing negative at a colorectal cancer screening: a randomized-controlled study.
    Knudsen MD; Hjartåker A; Olsen MKE; Hoff G; de Lange T; Bernklev T; Berstad P
    Eur J Cancer Prev; 2018 Jul; 27(4):316-322. PubMed ID: 27824661
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors influencing colonoscopy behaviour among Koreans with a positive faecal occult blood tests.
    Choi E; Jeon J; Kim J
    Eur J Cancer Care (Engl); 2019 Mar; 28(2):e13008. PubMed ID: 30748048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
    Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer worries and uptake of breast, cervical, and colorectal cancer screening: A population-based survey in England.
    Quaife SL; Waller J; von Wagner C; Vrinten C
    J Med Screen; 2019 Mar; 26(1):3-10. PubMed ID: 30249158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of a short message service intervention to motivate people with positive results in preliminary colorectal cancer screening to undergo colonoscopy: A randomized controlled trial.
    Wu Y; Liang Y; Zhou Q; Liu H; Lin G; Cai W; Li Y; Gu J
    Cancer; 2019 Jul; 125(13):2252-2261. PubMed ID: 30825395
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rethinking the Re-Prep: Attitudes Toward Noninvasive Colorectal Cancer Screening Tests After Inadequate Bowel Preparation.
    Platt KD; Kurlander JE; Zikmund-Fisher BJ; Lipson R; Knaus M; Waljee AK; Saini SD
    Am J Gastroenterol; 2019 Oct; 114(10):1685-1687. PubMed ID: 31464741
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Effect of a Health Education Intervention on Jordanian Participants' Colorectal Cancer Knowledge, Health Perceptions, and Screening Practices.
    Abuadas FH; Petro-Nustas WJ; Abuadas MH
    Cancer Nurs; 2018; 41(3):226-237. PubMed ID: 28252461
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
    Caviglia GP; Cabianca L; Fagoonee S; Gili FM
    Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels.
    Toes-Zoutendijk E; van Leerdam ME; Dekker E; van Hees F; Penning C; Nagtegaal I; van der Meulen MP; van Vuuren AJ; Kuipers EJ; Bonfrer JMG; Biermann K; Thomeer MGJ; van Veldhuizen H; Kroep S; van Ballegooijen M; Meijer GA; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I;
    Gastroenterology; 2017 Mar; 152(4):767-775.e2. PubMed ID: 27890769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.